PL1801209T3 - Zmodyfikowany genomowy RNA ludzkiego wirusa zapalenia wątroby typu C posiadający zdolność replikacji autonomicznej - Google Patents

Zmodyfikowany genomowy RNA ludzkiego wirusa zapalenia wątroby typu C posiadający zdolność replikacji autonomicznej

Info

Publication number
PL1801209T3
PL1801209T3 PL05781421T PL05781421T PL1801209T3 PL 1801209 T3 PL1801209 T3 PL 1801209T3 PL 05781421 T PL05781421 T PL 05781421T PL 05781421 T PL05781421 T PL 05781421T PL 1801209 T3 PL1801209 T3 PL 1801209T3
Authority
PL
Poland
Prior art keywords
coding sequence
protein coding
genomic rna
virus genomic
hepatitis
Prior art date
Application number
PL05781421T
Other languages
English (en)
Inventor
Takaji Wakita
Takanobu Kato
Tomoko Date
Michiko Miyamoto
Ralf Bartenschlager
Jun-Ichi Tanabe
Saburo Sone
Original Assignee
Toray Industries
Tokyo Metropolitan Inst Medical Science
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries, Tokyo Metropolitan Inst Medical Science filed Critical Toray Industries
Publication of PL1801209T3 publication Critical patent/PL1801209T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24241—Use of virus, viral particle or viral elements as a vector
    • C12N2770/24243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Pathology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
PL05781421T 2004-08-24 2005-08-24 Zmodyfikowany genomowy RNA ludzkiego wirusa zapalenia wątroby typu C posiadający zdolność replikacji autonomicznej PL1801209T3 (pl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP2004243975 2004-08-24
JP2004290801 2004-10-01
JP2005069527 2005-03-11
JP2005069725 2005-03-11
PCT/JP2005/015833 WO2006022422A1 (ja) 2004-08-24 2005-08-24 自律複製能を有する改変されたヒトｃ型肝炎ウイルスゲノムrna
EP05781421A EP1801209B1 (en) 2004-08-24 2005-08-24 Modified human hepatitis c virus genomic rna having autonomous replicative competence

Publications (1)

Publication Number Publication Date
PL1801209T3 true PL1801209T3 (pl) 2011-07-29

Family

ID=35967617

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05781421T PL1801209T3 (pl) 2004-08-24 2005-08-24 Zmodyfikowany genomowy RNA ludzkiego wirusa zapalenia wątroby typu C posiadający zdolność replikacji autonomicznej

Country Status (13)

Country Link
US (2) US8454973B2 (pl)
EP (1) EP1801209B1 (pl)
JP (1) JP4931591B2 (pl)
KR (1) KR101262773B1 (pl)
CN (1) CN101048502B (pl)
AT (1) ATE499442T1 (pl)
AU (1) AU2005275713B2 (pl)
CA (1) CA2578021C (pl)
DE (1) DE602005026545D1 (pl)
HK (1) HK1112481A1 (pl)
PL (1) PL1801209T3 (pl)
PT (1) PT1801209E (pl)
WO (1) WO2006022422A1 (pl)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006038129A2 (en) * 2004-10-01 2006-04-13 Novartis Vaccines And Diagnostics Srl Hepatitis c virus replication system
WO2006096459A2 (en) 2005-03-04 2006-09-14 The Rockefeller University Infectious, chimeric hepatitis c virus, methods of producing the same and methods of use thereof
US8364417B2 (en) * 2007-02-15 2013-01-29 454 Life Sciences Corporation System and method to correct out of phase errors in DNA sequencing data by use of a recursive algorithm
CN101390101B (zh) 2006-02-16 2012-05-23 454生命科学公司 用于校正核酸序列数据中的引物延伸误差的系统和方法
JP2008161080A (ja) * 2006-12-27 2008-07-17 Japan Health Science Foundation Ｃ型肝炎ウイルス阻害剤を検出するためのアッセイ方法
US8945584B2 (en) 2007-04-13 2015-02-03 Hvidovre Hospital Cell culture system of a hepatitis C genotype 3a and 2a chimera
US8454974B2 (en) 2007-04-13 2013-06-04 Hvidovre Hospital Adaptive mutations allow establishment of JFH1-based cell culture systems for hepatitis C virus genotype 4A
CN101688197A (zh) * 2007-04-27 2010-03-31 株式会社先端生命科学研究所 Hcv基因
US8618275B2 (en) 2007-05-18 2013-12-31 Hvidovre Hospital Efficient cell culture system for hepatitis C virus genotype 5A
US20100278865A1 (en) * 2007-07-13 2010-11-04 Takaji Wakita Production and use of epitope-tagged hepatitis c virus particle
US20100291545A1 (en) * 2007-07-25 2010-11-18 Takaji Wakita Antibody having inhibitory activity on infection with hepatitis c virus (hcv) and use thereof
US8563706B2 (en) 2007-12-20 2013-10-22 Hvidovre Hospital Efficient cell culture system for hepatitis C virus genotype 1A and 1B
US8569472B2 (en) 2007-12-20 2013-10-29 Hvidovre Hospital Efficient cell culture system for hepatitis C virus genotype 6A
WO2009131203A1 (ja) 2008-04-25 2009-10-29 東レ株式会社 C型肝炎ウイルス由来のキメラ遺伝子を含む核酸
US8663653B2 (en) 2008-08-15 2014-03-04 Hvidovre Hospital Efficient cell culture system for hepatitis C virus genotype 2B
WO2010017819A1 (en) 2008-08-15 2010-02-18 Hvidovre Hospital EFFICIENT CELL CULTURE SYSTEM FOR HEPATITIS C VIRUS GENOTYPE 7a
CN102227445B (zh) 2008-09-30 2014-12-17 东丽株式会社 结合丙型肝炎病毒的包膜蛋白2的抗体以及利用所述抗体鉴定丙型肝炎病毒的基因型的方法
US8772022B2 (en) 2008-10-03 2014-07-08 Hvidovre Hospital Hepatitis C virus expressing reporter tagged NS5A protein
JP5692738B2 (ja) * 2009-07-28 2015-04-01 国立大学法人 鹿児島大学 ウイルスの濃縮方法および磁性体組成物
US20120251572A1 (en) 2009-09-30 2012-10-04 Takaji Wakita Hepatitis c virus vaccine composition
US8592559B2 (en) 2009-10-30 2013-11-26 Toray Industries, Inc. Antibody having activity of inhibiting hepatitis C virus (HCV) infection and use thereof
WO2011156707A2 (en) 2010-06-11 2011-12-15 Life Technologies Corporation Alternative nucleotide flows in sequencing-by-synthesis methods
AU2011313158B2 (en) * 2010-10-08 2014-09-25 Advanced Life Science Institute, Inc. Hepatitis C virus gene
US8666678B2 (en) 2010-10-27 2014-03-04 Life Technologies Corporation Predictive model for use in sequencing-by-synthesis
US10273540B2 (en) 2010-10-27 2019-04-30 Life Technologies Corporation Methods and apparatuses for estimating parameters in a predictive model for use in sequencing-by-synthesis
EP2659408B1 (en) 2010-12-29 2019-03-27 Life Technologies Corporation Time-warped background signal for sequencing-by-synthesis operations
EP3582224A1 (en) 2010-12-30 2019-12-18 Life Technologies Corporation Models for analyzing data from sequencing-by-synthesis operations
WO2012092515A2 (en) 2010-12-30 2012-07-05 Life Technologies Corporation Methods, systems, and computer readable media for nucleic acid sequencing
US20130060482A1 (en) 2010-12-30 2013-03-07 Life Technologies Corporation Methods, systems, and computer readable media for making base calls in nucleic acid sequencing
EP2692861A4 (en) 2011-03-31 2014-12-17 Jp Nat Inst Infectious Disease NUCLEIC ACID CONSTRUCTURE WITH NUCLEIC ACID DERIVED FROM GENOTYP-1B HCV GENOMINE, THEREFORE, WITH HCV GENOM REPLICATED CELLS, AND METHOD FOR THE PRODUCTION OF INFECTIOUS HCV PARTICLES
EP3366782B1 (en) 2011-04-08 2021-03-10 Life Technologies Corporation Phase-protecting reagent flow orderings for use in sequencing-by-synthesis
CN103703133B (zh) 2011-05-31 2016-03-09 日本国立感染症研究所 来自丙型肝炎病毒j6cf株基因组的突变体复制子
AU2012302666B2 (en) 2011-08-31 2017-05-25 Inserm Institut National De La Sante Et De La Recherche Medicale Nucleic acid construct including nucleic acid derived from genotype 3a HCV genome
US10704164B2 (en) 2011-08-31 2020-07-07 Life Technologies Corporation Methods, systems, computer readable media, and kits for sample identification
JP2015509000A (ja) * 2012-01-13 2015-03-26 ギリアド ファーマセット エルエルシー Ｈｃｖポリメラーゼ複合体の結晶構造および使用方法
US9646132B2 (en) 2012-05-11 2017-05-09 Life Technologies Corporation Models for analyzing data from sequencing-by-synthesis operations
US10329608B2 (en) 2012-10-10 2019-06-25 Life Technologies Corporation Methods, systems, and computer readable media for repeat sequencing
US20140296080A1 (en) 2013-03-14 2014-10-02 Life Technologies Corporation Methods, Systems, and Computer Readable Media for Evaluating Variant Likelihood
US9926597B2 (en) 2013-07-26 2018-03-27 Life Technologies Corporation Control nucleic acid sequences for use in sequencing-by-synthesis and methods for designing the same
US10410739B2 (en) 2013-10-04 2019-09-10 Life Technologies Corporation Methods and systems for modeling phasing effects in sequencing using termination chemistry
WO2016060974A1 (en) 2014-10-13 2016-04-21 Life Technologies Corporation Methods, systems, and computer-readable media for accelerated base calling
WO2016183478A1 (en) 2015-05-14 2016-11-17 Life Technologies Corporation Barcode sequences, and related systems and methods
US10619205B2 (en) 2016-05-06 2020-04-14 Life Technologies Corporation Combinatorial barcode sequences, and related systems and methods

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE423204T1 (de) * 1996-11-08 2009-03-15 Us Gov Health & Human Serv Herstellung und reinigung von hepatitis c virus- ähnlichen partikeln
ATE362538T1 (de) * 1999-06-04 2007-06-15 Us Gov Health & Human Serv Klonierte genome von infektiösen hepatitis c viren genotyp 2a und deren verwendungen
PT1233782E (pt) * 1999-12-01 2009-02-13 Novartis Vaccines & Diagnostic Estimulação da produção de anticorpos específicos para o hcv
IL137522A (en) * 2000-07-26 2007-06-17 Drk Blutspendediendst Baden Wu HCV human monoclonal antibody E2 glycoprotein antibody
JP4880116B2 (ja) * 2000-12-01 2012-02-22 財団法人 東京都医学総合研究所 劇症ｃ型肝炎ウイルス株の遺伝子
US20050250093A1 (en) 2002-04-03 2005-11-10 Gates Adam T Hepatitis c virus sub-genomic replicons
CN1833024B (zh) * 2003-05-26 2011-08-31 东丽株式会社 含有衍生自基因型2a丙肝病毒(HCV)基因组的核酸的核酸构建体和具有转移入其中的这样的核酸构建体的细胞
WO2006038129A2 (en) * 2004-10-01 2006-04-13 Novartis Vaccines And Diagnostics Srl Hepatitis c virus replication system
WO2006096459A2 (en) 2005-03-04 2006-09-14 The Rockefeller University Infectious, chimeric hepatitis c virus, methods of producing the same and methods of use thereof
WO2009131203A1 (ja) * 2008-04-25 2009-10-29 東レ株式会社 C型肝炎ウイルス由来のキメラ遺伝子を含む核酸

Also Published As

Publication number Publication date
AU2005275713B2 (en) 2010-08-05
PT1801209E (pt) 2011-05-26
HK1112481A1 (en) 2008-09-05
CA2578021C (en) 2014-11-18
AU2005275713A1 (en) 2006-03-02
US20130115592A1 (en) 2013-05-09
EP1801209A4 (en) 2007-12-05
US20090176200A1 (en) 2009-07-09
CA2578021A1 (en) 2006-03-02
EP1801209A1 (en) 2007-06-27
ATE499442T1 (de) 2011-03-15
JP4931591B2 (ja) 2012-05-16
WO2006022422A1 (ja) 2006-03-02
KR101262773B1 (ko) 2013-05-10
EP1801209B1 (en) 2011-02-23
US8454973B2 (en) 2013-06-04
CN101048502A (zh) 2007-10-03
US9175269B2 (en) 2015-11-03
JPWO2006022422A1 (ja) 2008-05-08
CN101048502B (zh) 2012-03-21
KR20070045333A (ko) 2007-05-02
DE602005026545D1 (de) 2011-04-07

Similar Documents

Publication Publication Date Title
HK1112481A1 (en) Modified human hepatitis c virus genomic rna having autonomous replicative competence
Mandl et al. Spontaneous and engineered deletions in the 3′ noncoding region of tick-borne encephalitis virus: construction of highly attenuated mutants of a flavivirus
WO2009014216A1 (ja) Ｃ型肝炎ウイルス（hcv）に対して感染阻害活性を有する抗体およびその用途
Jones et al. The hepatitis C virus NS4B protein can trans-complement viral RNA replication and modulates production of infectious virus
Fan et al. The intrinsic disorder status of the human hepatitis C virus proteome
Ezelle et al. Generation of hepatitis C virus-like particles by use of a recombinant vesicular stomatitis virus vector
WO2006096459A3 (en) Infectious, chimeric hepatitis c virus, methods of producing the same and methods of use thereof
JP2008516610A5 (pl)
EP1930416A4 (en) NEW RECOMBINANT PARTICLE SIMILAR TO HUMAN HEPATITIS C VIRUS AND METHOD FOR THE MANUFACTURE THEREOF
HK1092498A1 (en) Composition containing the polyprotein ns3/ns4 and the polypeptide ns5b of hcv, expression vectors comprising corresponding nucleic sequences and the therapeutic application thereof
Imhof et al. Development of an intergenotypic hepatitis C virus (HCV) cell culture method to assess antiviral susceptibilities and resistance development of HCV NS3 protease genes from HCV genotypes 1 to 6
Londono-Renteria et al. A brief review of West Nile virus biology
Tajima et al. Restoration of replication-defective dengue type 1 virus bearing mutations in the N-terminal cytoplasmic portion of NS4A by additional mutations in NS4B
ATE555800T1 (de) Zusammensetzung mit dem polyprotein ns3/ns4 und dem polypeptid ns5b von hcv, expressionsvektoren mit den entsprechenden nukleinsäuresequenzen und ihre therapeutische verwendung
Khasnatinov et al. Tick-borne encephalitis virus structural proteins are the primary viral determinants of non-viraemic transmission between ticks whereas non-structural proteins affect cytotoxicity
Lattwein et al. Pestivirus virion morphogenesis in the absence of uncleaved nonstructural protein 2-3
Manickam et al. Modeling HCV disease in animals: virology, immunology and pathogenesis of HCV and GBV-B infections
Bittar et al. Genetic diversity of NS5A protein from hepatitis C virus genotype 3a and its relationship to therapy response
Sarwar et al. NS4A protein as a marker of HCV history suggests that different HCV genotypes originally evolved from genotype 1b
McElroy et al. Characterization of an infectious clone of the wild-type yellow fever virus Asibi strain that is able to infect and disseminate in mosquitoes
WO2008136470A1 (ja) Ｈｃｖ遺伝子
WO2005032329A3 (en) Methods and compositions for identifying anti-hcv agents
Pham et al. Efficient hepatitis C virus genotype 1b core-NS5A recombinants permit efficacy testing of protease and NS5A inhibitors
Suzuki et al. Positively selected amino acid sites in the entire coding region of hepatitis C virus subtype 1b
WO2016066171A1 (en) Optimized hcv full-length infectious cell culture systems and applications thereof